CINCINNATI—Prostate cancer is the second most common cancer in American men; about one in six will be diagnosed with prostate cancer during his lifetime.
September is Prostate Cancer Awareness Month, and men in the Tristate who suspect they may have prostate cancer or need to receive biopsies can have a more accurate diagnosis with quicker detection and intervention thanks to technologies only offered at UC Health.
Sadhna Verma, MD, a member of the University of Cincinnati Cancer Institute, associate professor in the department of radiology at the UC College of Medicine and a UC Health radiologist, says the UC Health team is the only one in the Tristate area that offers multi-parametric magnetic resonance imaging (mp-MRI) scans for cancer detection and MRI as a guidance tool for prostate biopsies.
"We offer several pre-operative imaging techniques that can help us decide whether to remove or spare delicate vascular bundles that surround the prostate gland,” she says, adding that magnetic resonance spectroscopic imaging (MRS) is used to detect normal and cancer-related chemical compounds in the prostate gland.
Additionally, experts agree that MR diffusion and MR perfusion—specifically imaging cancer cell "crowding” and maps of blood flow, which increase in cancer cells—assist with detection and help physicians decide how to proceed.
Verma says that when a biopsy is needed, the suspicious findings on the mp-MRI can be targeted for direct MRI-guided biopsy or MRI-ultrasound fusion targeted biopsy.
The fusion-targeted biopsy involves coupling of MRI and ultrasound to visualize suspicious lesions in the prostate gland.
Verma led a clinical trial at UC prior to the FDA-approval of the MRI guided biopsy technology. Now, she along with UC Cancer Institute and UC Health urologists Krishnanath Gaitonde, MD, James Donovan, MD, and Nilesh Patil, MD, are trained to use this technology at UC Medical Center.
"It’s a more efficient, effective way to biopsy for physicians and is much better for patients who previously had to undergo blind biopsy, which could involve them being stuck with a needle 12 or more times,” Verma adds.
Thefusion-targeted biopsy technology works by using an electro-magnetic navigation system, similar to a GPS tracking device. The MRI and ultrasound images are aligned and overlaid on real-time ultrasound and targets—which are identified and labeled high, medium or low suspicion for cancer—are displayed on ultrasound, which is based on the MRI exam findings.
Using MRI-guided biopsy technology, areas of the prostate that may not be sampled by the standard procedure are accessible; the standard ultrasound biopsy procedure samples the back portions of the prostate gland, meaning tumors located in the very front of the gland can be missed.
"The technologies we use are allowing us to diagnose and begin treating patients for better outcomes,” Verma says. "We’re happy to offer these services to area patients with hopes of improving and saving lives; however, the first step is being aware of your risks. If you have a family history of this cancer or are experiencing any symptoms of prostate cancer—trouble urinating, blood in your semen or urine or pain in the lower body or pelvis—please see your physician. ”